TFP
AXSM icon

Tilia Fiduciary Partners’s Axsome Therapeutics AXSM Stock Holding History

Tilia Fiduciary Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-136
Closed -$6K – 509
2022
Q2 		$6K Hold
136
– – 0.01% 416
2022
Q1 		$6K Hold
136
– – 0.01% 435
2021
Q4 		$5K Buy
+136
New +$5K ﹤0.01% 465

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Tilia Fiduciary Partners's AXSM Position: Q3 2022 in Review

Tilia Fiduciary Partners sold out of Axsome Therapeutics (AXSM) in Q3 2022, closing a stake of 136 shares — an estimated $6K sold.

Tilia Fiduciary Partners first reported a position in AXSM in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q2 2022. 189 funds tracked by Wall St. Rank hold AXSM as of Q3 2022.

  • Tilia Fiduciary Partners reported no remaining Axsome Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Tilia Fiduciary Partners sold 136 Axsome Therapeutics shares in Q3 2022, an estimated $6K.
  • Tilia Fiduciary Partners first reported a position in Axsome Therapeutics in Q4 2021 and held it in 3 quarters.
  • Tilia Fiduciary Partners's Axsome Therapeutics position peaked at $6K in Q2 2022.
  • 189 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2022.

Based on Tilia Fiduciary Partners's 13F filing for Q3 2022, filed 27 Oct 2022.